ClinicalTrials.gg
Active, not recruitingNCT06579287Updated Jan 23, 2026

A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control

A Phase 2 interventional study of SHJ002 and Atropine in Myopia, Progressive, sponsored by Sunhawk Vision Biotech, Inc.. Active, not recruiting at 9 sites in 2 countries. Open to participants aged 3 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Sunhawk Vision Biotech, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
3 Years to 12 Years
Sex
All
01

Study summary

The objective of this study is to explore the safety and efficacy of SHJ002 Sterile Ophthalmic Solution relative to atropine in myopia control

SHJ002 is an antisense oligonucleotide to neutralize a specific microRNA.

02

Conditions studied

  • Myopia, Progressive

Keywords

  • Myopia
03

In context

Myopia, Degenerative

71 studies on the registry are indexed under Myopia, Degenerative; 20 are open to participants now.

This study's enrollment of 140 is above the median of 122 across 57 interventional studies indexed under Myopia, Degenerative.

Browse Myopia, Degenerative studies →

Lead sponsor

Sunhawk Vision Biotech, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be male or female, age 3-12 years (inclusive).
  2. Cycloplegic sphere of -1.00 D or worse in both eyes
  3. Able to complete all study assessments and comply with the protocol
  4. Literate or able to orally communicate.
  5. Parent or guardian able and willing to provide written
  6. Parent or guardian able and willing to assure subject compliance with the protocol, follow study instructions, and attend study visits
  7. Able to tolerate eye drops in both eyes.
  8. Be able and willing to avoid all disallowed medications and refractive correction
  9. For female subjects of (those who have experienced menarche and who are not surgically sterilized [bilateral tubal ligation, hysterectomy, or bilateral oophorectomy]), a negative urinary test.
  10. Women of childbearing potential must agree to use two reliable methods of
  11. Males not naturally or surgically sterile, who have a female partner of childbearing potential, must agree to use two reliable methods of contraception

Exclusion criteria

Exclusion Criteria:

  1. Axial length > 26 mm
  2. Anisometropia
  3. Astigmatism > 2.00 D
  4. Intraocular pressure > 21 mm Hg or \< 6 mm Hg
  5. Active or recent history of severe ocular infection or inflammation
  6. Previous incisional or laser surgery
  7. Any finding on slit lamp biomicroscopy or ophthalmoscopy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    SHJ002

    The assigned eyedrops will be instilled in both eyes once per day, one drop per application, 7 days a week, for 52 weeks.

    Drug: SHJ002

  • Active comparator
    Atropine

    The assigned eyedrops will be instilled in both eyes once per day, one drop per application, 7 days a week, for 52 weeks.

    Drug: Atropine

Interventions

  • DrugSHJ002

    Topical ophthalmic

  • Topical ophthalmic

06

What researchers measure

Primary outcomes

  1. Change of the cycloplegic spherical equivalent (SE)

    Time frame: from baseline visit to the final visit, up to 52 weeks

Secondary outcomes

  1. Change of axial length

    Time frame: from baseline visit to the final visit, up to 52 weeks

07

Study locations

9 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2024
First posted
Aug 30, 2024
StartActual
Jan 22, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06579287
Lead sponsor
Sunhawk Vision Biotech, Inc.
Responsible party
Sponsor
First posted
Aug 30, 2024
Start date
Jan 22, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion